Article Sidebar
Published:
Jul 20, 2021Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
3-Cinnamoyl-4-hydroxy-6-methyl-2H-pyran-2-one ameliorates diabetic peripheral neuropathy in type 2 diabetes mellitus rats via PI3K/Akt signaling pathway
Abstract
Purpose: To investigate the curative effects of 3-cinnamoyl-4-hydroxy-6-methyl-2H-pyran-2-one (CHMP) on streptozotocin (STZ)-induced model of diabetic SD rats, and the underlying mechanism.
Method: Diabetes was induced in rats using single intraperitoneal injection of STZ. Subsequently, diabetic and non-diabetic rats were randomly grouped into five experimental groups. Six weeks after the STZ-injection, the diabetic animals were orally administered test compound (CHMP) at two doses of 10 and 20 mg/kg body weight for 6 weeks. Thereafter, the rats were anesthetised, and body weight, blood sugar, and motor nerve conduction velocity (MNCV) were determined. Moreover, real time-polymerase chain reaction (RT-PCR) and western blot analysis were used to assay the expression levels of genes in PIK3/Akt pathway and Glut4.
Results: Treatment of diabetic rats with CHMP significantly reduced levels of fasting blood glucose and enhanced average rat body weight, relative to diabetic control (p ˂ 0.05). Motor nerve conduction velocity (MNCV) was remarkably increased in CHMP-treated rats (54.2 ± 2.2), when compared to the diabetic control rats (46 ± 4.1, p < 0.01). Results from RT-PCR and western blot indicated increased expressions of PI3K, Akt and IRS-1, and down regulation of GSK-3B expression in skeletal muscle. The CHMP treatment also upregulated the Glut4 expression in skeletal muscle.
Conclusion: These findings show that CHMP may be beneficial in the management of diabetic neuropathy
